---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-022763"
form_type: "8-K"
ticker: "SGMT"
cik: "0001400118"
company_name: "Sagimet Biosciences Inc."
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T22:12:15.615463+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sagimet reports FY2024 net loss of $45.6M; advances denifanstat Phase 3 in MASH and TVB-3567 IND clearance

## Summary
- Full year 2024 net loss $45.6M ($27.9M in 2023); R&D expense $38.4M, up from $19.8M.
- Cash $158.7M at Dec 31, 2024; funded by Jan 2024 follow-on offering of 9M shares netting $104.7M.
- Phase 3 denifanstat program for MASH initiated; patient screening expected 1H 2025; includes FASCINATE-3 and FASCINIT.
- FDA granted Breakthrough Therapy designation for denifanstat in non-cirrhotic MASH with F2/F3 fibrosis.
- IND cleared for TVB-3567, a second FASN inhibitor for acne; Phase 1 trial planned in 2025.

## SEC filing metadata
- accession: 0001104659-25-022763
- form_type: 8-K
- ticker: SGMT
- cik: 0001400118
- company_name: Sagimet Biosciences Inc.
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1400118/000110465925022763/0001104659-25-022763-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1400118/000110465925022763/tm258742d4_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-022763
- JSON: https://secwatch.observer/filing/0001104659-25-022763.json
- Plain text: https://secwatch.observer/filing/0001104659-25-022763.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.